Kinase News and Research

RSS

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

The uncontrolled growth of cancer cells arises from their ability to hijack the cell’s normal growth program and checkpoints. Usually after therapy, a second cancer-signaling pathway will open after the primary one shuts down — creating an ingenious escape route for the cancer cell to survive. The answer, say Case Western Reserve researchers, is to anticipate and block that back-up track by prescribing two drugs from the start.

29 Oct 2014

TSRI scientists discover signaling pathway that contribute to Huntington's disease

Scientists from the Florida campus of The Scripps Research Institute have uncovered a major contributor to Huntington's disease, a devastating progressive neurological condition that produces involuntary movements, emotional disturbance and cognitive impairment.

29 Oct 2014

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.

28 Oct 2014

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.

27 Oct 2014

Researchers identify compounds that could lead to discovery of new drugs for African sleeping sickness

In early drug discovery, you need a starting point, says Northeastern University associate professor of chemistry and chemical biology Michael Pollastri.

27 Oct 2014

Preeclampsia study provides pathways for new therapeutic treatments

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.

27 Oct 2014

Research could pave way for more effective drugs to treat inflammation

Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis.

25 Oct 2014

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers.

22 Oct 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

Study reveals inner workings of PKA switch that regulates cellular functions, contributes to deadly disorders

A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.

13 Oct 2014

Researchers reveal new information about Protein Kinase A

Using X-rays and neutron beams, a team of researchers from the University of California, San Diego School of Medicine, University of Utah and Oak Ridge National Laboratory have teased out new information about Protein Kinase A (PKA), a ubiquitous master switch that helps regulate fundamental cellular functions like energy consumption and interactions with hormones, neurotransmitters and drugs.

10 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

New model predicts replication rate in genome-wide studies based on SNP characteristics

To reduce false positives when identifying genetic variations associated with human disease through genome-wide association studies (GWAS), Dartmouth researchers have identified nine traits that are not dependent on P values to predict single nucleotide polymorphisms (SNP) reproducibility as reported in Human Genetics on October 2, 2014.

9 Oct 2014

ERK and JNK enzymes may offer solutions for treating endometrial, colon cancers

In the quest to solve cancer's mysteries, they come in handy when describing tongue-twisting processes and pathways that somehow allow tumors to form and thrive. Two examples are ERK (extracellular-signal-related kinase) and JNK (c-June N-Terminal Kinase), enzymes that may offer unexpected solutions for treating some endometrial and colon cancers.

3 Oct 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Kinase News and Research

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

TSRI scientists discover signaling pathway that contribute to Huntington's disease

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

Researchers identify compounds that could lead to discovery of new drugs for African sleeping sickness

Preeclampsia study provides pathways for new therapeutic treatments

Research could pave way for more effective drugs to treat inflammation

Afatinib active against NSCLC nervous system metastases

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Study reveals inner workings of PKA switch that regulates cellular functions, contributes to deadly disorders

Researchers reveal new information about Protein Kinase A

VAL-083 drug compound shows promise against non-small cell lung cancer

New model predicts replication rate in genome-wide studies based on SNP characteristics

ERK and JNK enzymes may offer solutions for treating endometrial, colon cancers

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Combination therapy achieves greater progression-free survival, response rates in melanoma

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News